Immunocytochemistry with monoclonal antibody B72.3 applied to a spectrum of benign and malignant breast aspirates — strengths and pitfalls Joel LundyMary LozowskiYousri Mishriki Report Pages: 259 - 266
Steroid hormone receptors and prognosis in breast cancer Günter DaxenbichlerErnst-Pius ForsthuberOtto Dapunt Report Pages: 267 - 273
Age-of-onset heterogeneity in hereditary breast cancer: Minimal clues for diagnosis Henry T. LynchTheresa ConwayJane F. Lynch Report Pages: 275 - 285
Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors Paulo G. SpinolaBianca MarchettiFernand Labrie Report Pages: 287 - 296
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years Richard R. LoveRichard B. MazessV. Craig Jordan Report Pages: 297 - 302
Complete remission after ovariectomy for advanced breast cancer correlated with estrogen receptor status and urinary androgen excretion Saro OrianaGiorgio SecretoAndrea Torri Brief communication Pages: 303 - 305
Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels G. BertelliP. PronzatoR. Rosso Brief communication Pages: 307 - 310
Primary synchronous bilateral breast cancer: Epidemiological approach Joseba Kelmendi de UstaránRoberto Pablo Meiss Brief communication Pages: 311 - 314
The synthetic retinoid Fenretinide does not affect circulating hormone concentrations G. SecretoA. CostaP. Ballerini Correspondence Pages: 315 - 316
Inability of tamoxifen to penetrate into cerebrospinal fluid Shinzaburo NoguchiKeisuke MiyauchiHiroki Koyama Correspondence Pages: 317 - 318
Comment on ‘New lumps in the breast following conservation treatment for early breast cancer’ A. P. LockerE. J. RoebuckR. W. Blamey Correspondence Pages: 319 - 319
